Fosun has signed an agreement to buy the Dead Sea cosmetics company from its shareholders.
The European global satellite provider is in talks to buy the Lod-based digital media services company.
Mergers & acquisitions
Perrigo's latest acquisition comes as it completes the $200 million buy of GSK's OTC portfolio.
The establishment of the government's Urban Renewal Authority brings new opportunities.
Teva led the losses on the market as Delek lost more ground but Israel Chemicals rose.
Haim Siboni hopes to be one of the 3 top players in the autonomous vehicle market, and bring thousands of jobs to Israel.
Transport & infrastructure
The 2015-2016 school year began today at 4,805 educational institutions in Israel.
FXCM Israel: The shekel-dollar pair is trying to break through the resistance atNIS 3.94-3.95/$.
Analysts fear that share prices of the Tamar and Leviathan partners could fall further.
Predictions of the consequences for Israel of the Egyptian gas discovery have cut loose from the facts.
"We view the industry as fundamentally attractive."
CEO and Owner Elsmed Group
888 and Bwin agreed a $1.4 billion deal in July, but rival GVC countered with a $1.55 billion bid.
Israel's new Supervisor of Banks wants the banks to be allowed to sell insurance.
Experts tell "Globes" that the chances of Leviathan exports to Egypt are slim and suggest Turkey as an alternative.
ZECUITY is a disposable patch system, worn for four-hours on the upper arm or thigh, that delivers sumatriptan through the skin.
The Casual Connect conference is being organized by the Casual Games Association with local company Playtika.
Senior gas sector executive: The natural gas agreement is not just stuck, it won't be implemented.
Claudio Descalzi told La Repubblica his company was not necessarily looking to sell a stake in the Zohr field.
Dganit Rockach's new coworking space allows hardworking startup employees to take a coding break and physically surf.
It looks as though Leviathan will not be developed, an outcome that could easily have been avoided.